Closing Reflections on BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma

In the closing remarks, Dr. Shambavi Richard reflects on the key themes that emerged throughout the discussion on the evolving role of BCMA-directed therapies in relapsed/refractory multiple myeloma (R/R MM). She emphasizes the ongoing challenge of integrating rapidly expanding clinical trial data into evidence-based treatment decisions while accounting for patient access, caregiver support, treatment eligibility, and other real-world considerations. Highlighting the need for thoughtful sequencing of CAR-T cell therapies and bispecific antibodies, she notes that many clinical decisions continue to rely on expert judgment because definitive sequencing data remain limited. After reviewing the key debate topics, Dr. Richard announces the winning team and concludes by reinforcing that there is rarely a single correct treatment approach in relapsed/refractory multiple myeloma. Instead, optimizing patient outcomes requires individualized treatment selection, careful sequencing of available therapies, and continued generation of clinical evidence to guide practice as the therapeutic landscape continues to evolve.